De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD
Authors:
- Yael HacohenYHYael Hacohen
- Géraldine AndrodiasGAGéraldine Androdias
- Georgina ArrambideGAGeorgina Arrambide
- Arlette Laurien BruijstensABArlette Laurien Bruijstens
- Olga CiccarelliOCOlga Ciccarelli
- Alvaro Cobo-CalvoACAlvaro Cobo-Calvo
- Eoin P. FlanaganEFEoin P. Flanagan
- Ho Jin KimHKHo Jin Kim
- Ellen IacobaeusEIEllen Iacobaeus
- Jan D. LünemannJLJan D. Lünemann
- Bruno StankoffBSBruno Stankoff
- Mar TintoreMTMar Tintore
Open Access
- 22 September 2026
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (6) , e218482
Abstract
Antibody-mediated inflammatory diseases of the CNS, including aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-Ab NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated...Keywords
This publication has 60 references indexed in Scilit:
- Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseJAMA Neurology, 2026
- Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG–Positive Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2025
- Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisJAMA Neurology, 2025
- Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseJAMA Neurology, 2024
- B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activityAnnals of Clinical and Translational Neurology, 2024
- Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacksAnnals of Clinical and Translational Neurology, 2022
- Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseJAMA Neurology, 2022
- Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum DisorderJAMA Network Open, 2021
- Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody DiseasesAnnals of Neurology, 2019
- Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseJAMA Neurology, 2018